LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Inicio・Lista de Acciones・Erasca Inc

Erasca Inc

Cerrado

13.81 7.81

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.81

Máximo

14.97

Métricas clave
By Trading Economics
Ingresos	-154M -183M
BPA	-0.6
Empleados	103
EBITDA	-5.3M -37M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+57.87% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	249M 3.5B
Apertura anterior	6
Cierre anterior	13.81

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 may 2026, 22:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 may 2026, 23:08 UTC

Adquisiciones, fusiones, absorciones

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 may 2026, 20:53 UTC

Ganancias

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 may 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 20:33 UTC

Charlas de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 may 2026, 20:11 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 19:47 UTC

Ganancias

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 may 2026, 19:36 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 may 2026, 19:22 UTC

Charlas de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 may 2026, 19:05 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 may 2026, 18:19 UTC

Charlas de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 may 2026, 18:12 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 may 2026, 18:11 UTC

Charlas de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 may 2026, 18:10 UTC

Charlas de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 may 2026, 17:55 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 17:55 UTC

Charlas de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 may 2026, 17:00 UTC

Ganancias

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

29 may 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

29 may 2026, 16:02 UTC

Charlas de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

57.87% repunte

Estimación a 12 Meses

Media 20.27 USD 57.87%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.